Oppenheimer analyst Hartaj Singh notes that Sarepta provided an update on its 4053-101 study, a two-part study designed to assess the safety, tolerability and pharmacokinetics of four dose levels of SRP-4053 and an open-label evaluation of SRP-4053 in patients with deletions amenable to exon 53 skipping. The positive result removes an overhang on Sarepta, he contends, as some investors had posited that weak biopsy results from 4053-101 could reignite the Exondys 51 approval controversy from 2H16. The analyst reiterates an Outperform rating and $76 price target on the shares.